Newly-Recognized Roles of Factor XIII in Thrombosis.

abstract：:In the past two decades, major improvements in antibiotics and other elements of supportive care have decreased the number and severity of complications of hematopoietic stem cell transplantation (HSCT). Despite these improvements, many subpopulations of transplant patients still have a significant morbidity and morta...

journal_title：Seminars in thrombosis and hemostasis

authors： Haire WD

更新日期：1999-01-01 00:00:00

abstract：:In order to assess inhibitor development in previously untreated patients (PUPs) with severe (factor VIII [FVIII]<1%) and moderate (FVIII 1 to 5%) hemophilia A, a prospective study was initiated in 1976. During the 23-year study period, 72 hemophiliacs were frequently exposed prophylactically or on demand to plasma-de...

journal_title：Seminars in thrombosis and hemostasis

authors： Kreuz W,Ettingshausen CE,Zyschka A,Oldenburg J,Saguer IM,Ehrenforth S,Klingebiel T

更新日期：2002-06-01 00:00:00

abstract：:Although the current therapeutic armamentarium of venous thrombosis encompasses the use of vitamin K antagonists, heparins, and direct oral anticoagulants, these drugs have several important drawbacks. Antisense oligonucleotides are relatively short single-stranded nucleic acid sequences, which hybridize with a target...

journal_title：Seminars in thrombosis and hemostasis

authors： Lippi G,Harenberg J,Mattiuzzi C,Favaloro EJ

更新日期：2015-03-01 00:00:00

abstract：:Total fibrinolytic activity in the vasculature is finely tuned by the balance between tissue plasminogen activator and plasminogen activator inhibitor type 1 (PAI-1). Although PAI-1 targets plasminogen activators, it also reacts with other serine proteases such as thrombin and factor Xa. The latter was shown to intera...

journal_title：Seminars in thrombosis and hemostasis

authors： Urano T,Ihara H,Suzuki Y,Takada Y,Takada A

更新日期：2000-01-01 00:00:00

abstract：:Current guidelines for venous thromboembolism (VTE) primary prophylaxis are based on randomized clinical trials that exclude subjects at a potentially high bleeding risk. Thus no specific recommendation/algorithm for pharmacological prophylaxis in patients with thrombocytopenia and/or platelet dysfunction is available...

journal_title：Seminars in thrombosis and hemostasis

authors： Tufano A,Guida A,Di Minno MN,Prisco D,Cerbone AM,Di Minno G

更新日期：2011-04-01 00:00:00

abstract：:Atherosclerosis is the major underlying cause of cardiovascular diseases, the prevalence of which is continuously increasing, thus currently standing as the leading global cause of death. This pathology gradually develops over the course of 50 or more years throughout the life of an individual under the influence of a...

journal_title：Seminars in thrombosis and hemostasis

authors： Larivière M,Bonnet S,Lorenzato C,Laroche-Traineau J,Ottonès F,Jacobin-Valat MJ,Clofent-Sanchez G

更新日期：2020-07-01 00:00:00

abstract：:Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), mainly polycythemia vera and essential thrombocythemia. Pathogenesis of blood clotting activation in these diseases is multifactorial, and i...

journal_title：Seminars in thrombosis and hemostasis

authors： Falanga A,Marchetti M

更新日期：2014-04-01 00:00:00

abstract：:Immune thrombocytopenic purpura (ITP) is a bleeding disorder and is traditionally divided in acute and chronic forms based on the duration of the disease. Chronic ITP is characterized by a persistence of thrombocytopenia for more than 6 months. Ten to 20% of children with ITP and almost all adults will develop the chr...

journal_title：Seminars in thrombosis and hemostasis

authors： Kühne T,Imbach P

更新日期：1998-01-01 00:00:00

abstract：:Patients receiving oral anticoagulant treatment have abnormally low levels of functional vitamin K-dependent coagulation proteins and consequently a clear risk of hemorrhagic complications. The incidence of hemorrhages has been reported to be around 0.6-0.7% per month at a therapeutic International Normalized Ratio (I...

journal_title：Seminars in thrombosis and hemostasis

authors： Berntorp E

更新日期：2000-01-01 00:00:00

abstract：:With the continued accumulation of clinical and animal studies, it is becoming abundantly clear that the protein C anticoagulant pathway plays a critical role in the regulation of coagulation. Investigations also indicate that this pathway is intimately involved in the interaction of the coagulation and inflammatory s...

journal_title：Seminars in thrombosis and hemostasis

authors： Esmon NL,Esmon CT

更新日期：1988-04-01 00:00:00

abstract：:Thrombocytosis is frequently (10 to 57%) observed in cancer patients. Although the mechanisms underlying thrombocytosis are not yet fully elucidated, tumor-derived factors with thrombopoietin-like activity, growth factors, platelet-derived microparticles, and factors released from bone marrow endothelial cells as well...

journal_title：Seminars in thrombosis and hemostasis

authors： Sierko E,Wojtukiewicz MZ

更新日期：2007-10-01 00:00:00

abstract：:Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at positions 158, 296, and 298, respectively. These substitutions result in considerable enhancement ...

journal_title：Seminars in thrombosis and hemostasis

authors： Persson E,Olsen OH,Bjørn SE,Ezban M

更新日期：2012-04-01 00:00:00

abstract：:Each bone marrow megakaryocyte (MK) releases thousands of platelets into the circulation, and the underlying molecular and cellular mechanisms recently have received intense scrutiny. Genetic studies are beginning to clarify the mechanisms by which transcription factors help distinguish MK progenitors from other blood...

journal_title：Seminars in thrombosis and hemostasis

authors： Schulze H,Shivdasani RA

更新日期：2004-08-01 00:00:00

abstract：:The number of hip fractures in anticoagulated patients is predicted to increase, due to people living longer. However, evidence regarding urgent perioperative management of elderly patients with hip fracture who take oral anticoagulants (vitamin K antagonists or direct oral anticoagulants) is scarce. In this article, ...

journal_title：Seminars in thrombosis and hemostasis

authors： Grandone E,Ostuni A,Tiscia GL,Marongiu F,Barcellona D

更新日期：2019-03-01 00:00:00

abstract：:C-type lectin-like receptor 2 (CLEC-2) has been identified on the surface of platelets as a receptor for a platelet activating snake venom, rhodocytin/aggretin. CLEC-2 belongs to a C-type lectin superfamily and binds to a sialoglycoprotein, podoplanin, in vivo. Platelets play a crucial role in hemostasis and thrombosi...

journal_title：Seminars in thrombosis and hemostasis

authors： Suzuki-Inoue K,Tsukiji N,Shirai T,Osada M,Inoue O,Ozaki Y

更新日期：2018-03-01 00:00:00

abstract：:In this short review I have tried to report the literature findings and describe some of our observations on fibrinolysis and atherosclerosis. Although at this time it is difficult to state that diminished FA plays a pathogenic role in atherosclerosis, it certainly seems to represent a risk factor. ...

journal_title：Seminars in thrombosis and hemostasis

authors： Balkuv-Ulutin S

更新日期：1986-04-01 00:00:00

abstract：:In this article, three cases, with antithrombin (AT) abnormality "Toyama" (type IIb), AT abnormality "Aomori" (type IIa), and congenital AT deficiency (type I) with pregnancy and delivery managed with administration of both AT concentrates and low-molecular-weight heparin, are described. Additionally, a case of AT-pro...

journal_title：Seminars in thrombosis and hemostasis

authors： Sakuragawa N

更新日期：1997-01-01 00:00:00

abstract：:The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increa...

journal_title：Seminars in thrombosis and hemostasis

authors： Cella G,Cipriani A,Tommasini A,Rampin E,Sbarai A,Rocconi R,Mazzaro G,Luzzatto G

更新日期：1997-01-01 00:00:00

abstract：:In order to obtain a global assessment of circulating clopidogrel-related products and of the excretion of the drug, the pharmacokinetic behavior and the excretion balance of 14C radioactivity following the administration of a single dose of 75 mg of 14C-labeled clopidogrel were compared in 6 clopidogrel-free healthy ...

journal_title：Seminars in thrombosis and hemostasis

authors： Lins R,Broekhuysen J,Necciari J,Deroubaix X

更新日期：1999-01-01 00:00:00

abstract：:Impaired placental development is a well-known pathogenesis in preeclampsia. The present study was undertaken to elucidate the involvement of fibrinolytic factors in amniotic fluid in midtrimester with development of severe early-onset preeclampsia. Amniotic fluid was obtained by amniocentesis at 15 to 18 weeks of ges...

journal_title：Seminars in thrombosis and hemostasis

authors： Adachi T,Nakabayashi M,Sakura M,Ando K

更新日期：1999-01-01 00:00:00

abstract：:Despite the improved therapeutic advances in the management of acute promyelocytic leukemia (APL), a significant early mortality during induction, also referred to as early death (ED), remains an obstacle for further improvement in outcome. Hemorrhagic complications are the most common cause of morbidity and mortality...

journal_title：Seminars in thrombosis and hemostasis

authors： Kwaan HC,Weiss I,Tallman MS

更新日期：2019-09-01 00:00:00

abstract：:Platelet aggregometry has been the reference method employed to detect, diagnose, and monitor qualitative platelet disorders since the early 1960s. Lumiaggregometry and impedance-based whole blood lumiaggregometry have advantages over light transmittance aggregometry in that they provide for enhanced specimen manageme...

journal_title：Seminars in thrombosis and hemostasis

authors： McGlasson DL,Fritsma GA

更新日期：2009-03-01 00:00:00

abstract：:Venous thromboembolism is a common complication in patients with acute thrombotic stroke. Estimates of the frequency of deep vein thrombosis (DVT) in untreated patients range from 20 to 75%. This wide range reported depends on the methods used to detect DVT and, importantly, on the degree of lower limb paralysis. Most...

journal_title：Seminars in thrombosis and hemostasis

authors： Turpie AG

更新日期：1997-01-01 00:00:00

abstract：:Polycystic ovarian syndrome (PCOS) affects 12 to 19% of women and has reproductive and metabolic features (endothelial dysfunction, increased diabetes, and cardiovascular risk factors). It also appears to have altered coagulation and fibrinolysis with a prothrombotic state with epidemiological evidence of increased ve...

journal_title：Seminars in thrombosis and hemostasis

authors： Burchall GF,Piva TJ,Linden MD,Gibson-Helm ME,Ranasinha S,Teede HJ

更新日期：2016-02-01 00:00:00

abstract：:Sequencing of the gene encoding for von Willebrand factor (VWF) has brought new insight into the physiology of VWF as well as its pathophysiology in the context of von Willebrand disease (VWD). Molecular testing in VWD patients has shown high variability in the overall genetic background of this condition. Almost 600 ...

journal_title：Seminars in thrombosis and hemostasis

authors： Zolkova J,Sokol J,Simurda T,Vadelova L,Snahnicanova Z,Loderer D,Dobrotova M,Ivankova J,Skornova I,Lasabova Z,Kubisz P,Stasko J

更新日期：2020-06-01 00:00:00

abstract：:Neutrophils have long been known as innate immune cells that phagocytose and kill pathogens and mount inflammatory responses protecting the host from infection. In the past decades, new aspects of neutrophils have emerged unmasking their importance not only in inflammation but also in many pathological conditions incl...

journal_title：Seminars in thrombosis and hemostasis

authors： Demers M,Wagner DD

更新日期：2014-04-01 00:00:00

abstract：:Epidemiological and laboratory studies performed in the last decades have changed our understanding of coagulopathy in cirrhosis, from a condition at increased risk of hemorrhagic events to one at higher thrombotic risk. However, it is not clear whether the decrease in factors that promote (except factor [F] VIII) ver...

journal_title：Seminars in thrombosis and hemostasis

authors： Lebreton A,Sinegre T,Lecompte T,Talon L,Abergel A,Lisman T

更新日期：2020-09-01 00:00:00

abstract：:The key reason behind the success of heparin in thrombosis and beyond is its polypharmacological sites of action for the prevention and treatment of multifactorial diseases that will only benefit slightly with single pharmacological mechanism-based agents. Thromboembolic disorders are driven by hypercoagulable, hypera...

journal_title：Seminars in thrombosis and hemostasis

authors： Mousa SA

更新日期：2007-07-01 00:00:00

abstract：:The international classification of functioning (ICF) has provided a basic framework for the measurement of outcomes in any health condition. This includes the assessment of the level of activity, participation, and the quality of life of an individual with hemophilia. The measure of activity is an assessment of the i...

journal_title：Seminars in thrombosis and hemostasis

authors： David JA,Feldman BM

更新日期：2015-11-01 00:00:00

abstract：:There is a persuasive body of evidence suggesting that tissue factor (TF) is a major determinant of tumor progression. In addition to its "traditional" function as the initiator of hemostasis, TF may support tumor progression through signaling mechanisms involving either direct signal transduction through the TF cytop...

journal_title：Seminars in thrombosis and hemostasis

authors： Palumbo JS

更新日期：2008-03-01 00:00:00